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 ABSTRACT 
 
Background: The natural history of ductal carcinoma in situ (DCIS) in contemporary 
practice remains uncertain. The risk factors for the development of invasive cancer in 
unresected DCIS are unclear. 
 
Methods: Women diagnosed with DCIS on needle biopsy after 1997 who did not 
undergo surgical resection for at least one year after diagnosis were identified by 
breast centers and the cancer registry and outcomes were reviewed. 
 
Results: Eighty-nine women with DCIS diagnosed 1998-2010 were identified. The 
median age at diagnosis was 75 (range 44-94) years with median follow-up 
(diagnosis to death, invasive disease or last review) of 59 (12-180) months. Twenty-
nine women (33%) developed invasive breast cancer after a median interval of 45 
(12-144) months. 14/29 (48%) with high grade, 10/31 (32%) with intermediate grade 
and 3/17 (18%) with low grade DCIS developed invasive cancer after median 
intervals of 38, 60 and 51 months. The cumulative incidence of invasion was 
significantly higher in high grade DCIS than other grades (p=0.0016, log-rank test). 
Invasion was more frequent in lesions with calcification as the predominant feature 
(23/50 v. 5/25; p=0.042) and in younger women (p=0.0002). Endocrine therapy was 
associated with a lower rate of invasive breast cancer (p=0.048).  
 
Conclusions: High cytonuclear grade, mammographic microcalcification, young age 
and lack of endocrine therapy were risk factors for progression of DCIS to invasive 
cancer. Guideline-concordant surgical excision of high grade DCIS remains the 
 treatment of choice. Eligible women with low grade DCIS could be offered entry into 
active surveillance trials. 
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 1. INTRODUCTION 
 
Ductal carcinoma in situ (DCIS) is diagnosed predominantly through mammographic 
screening programmes and now comprises 20% or more of new breast cancers. [1] Concern 
has been expressed regarding possible overtreatment, [2] given the excellent long term 
survival of women with DCIS. [3,4] Some have suggested that “nothing is better than 
something” [5] and proposed long-term surveillance for estrogen receptor (ER) positive 
DCIS. [6,7] Trials have opened in the UK, [8] US [9] and Europe [10] to investigate active 
surveillance (AS) as an alternative to surgery. 
 
While there is an historic literature describing the natural history of DCIS in small, 
predominantly pre-screening series of symptomatic disease, [11] there is also a growing 
understanding that DCIS is a heterogeneous condition. It has been reported as a common 
incidental finding at autopsy with a median 8.9% prevalence in a review of seven studies of 
women who died of unrelated causes. [12] These series, conducted over 30 years ago, used 
variable diagnostic criteria, compounded by the difficulty of diagnosing DCIS in tissue that is 
likely to have been poorly preserved. The current prevalence of undiagnosed DCIS therefore 
remains uncertain. 
 
Whatever the true prevalence, surgery, radiotherapy and endocrine therapy remain the 
mainstays of guideline-concordant care. However, some 2.0-2.3% of patients diagnosed 
with DCIS in the USA choose AS for management of their disease. [4,13] Without treatment, 
it has been estimated that only 20-30% of DCIS will progress to invasive cancer. [11,14] 
Furthermore, it is not known whether long-term disease outcome is adversely impacted by 
awaiting progression to invasive disease.   
 
Given this background, we sought to identify women in the recent breast screening era who 
had not received surgical resection for histologically diagnosed DCIS and to consider risk 
 factors and long-term outcomes for such women as a comparator for active surveillance 
trials. 
 
 
2. MATERIAL AND METHODS 
 
2.1. The West Midlands Cancer Intelligence Unit (WMCIU, now incorporated into the 
National Cancer Registration and Analysis Service, part of Public Health England) and the 
Scottish Cancer Registry identified 2505 possible eligible patients from cancer registrations 
of women diagnosed in England and Scotland between 1 January 1996 and 31 December 
2009. These women had a needle biopsy diagnosis of DCIS but no record of subsequent 
surgery. Details were sent to Lead Clinicians in each hospital following completion of a 
confidentiality agreement. In addition, National Health Service (NHS) Breast Units and NHS 
Breast Screening Programme (NHSBSP) centres in the United Kingdom were invited to 
submit details of known patients with DCIS diagnosed from 1 January 2010 onwards who 
had not undergone surgical excision for at least one year following confirmed histological 
diagnosis on needle biopsy. Additionally, some women diagnosed between 2003 and 2012 
were identified via the NHSBSP prospective cohort study of screen-detected non-invasive 
neoplasias, the Sloane Project (www.sloaneproject.org).  
 
A comprehensive registration form was completed for each case by the submitting centre, 
including details of the imaging and clinical findings, mode of biopsy, histopathology, 
reasons (where known) for not performing surgery and relevant drug treatment and/or 
radiotherapy. A follow-up form was completed for each subsequent episode, which included 
one or more of clinical assessment, mammogram and ultrasound. A third form was 
completed for any further needle biopsy or surgery. Forms were returned to the WMCIU / 
Public Health England where the data were entered onto a database. Missing data on 
tumour characteristics together with date and cause of death were obtained from the 
 National Cancer Registration and Analysis Service. Data were exported to an Excel 
spreadsheet for analysis. Registration opened in 2012 and closed in December 2016.  
 
2.2. Statistical methods 
Comparisons of categorical data were made using the Fisher Exact test.  Continuous 
variables were assessed by the Mann-Whitney U test. Cumulative incidence curves were 
compared using Kaplan-Meier analysis and the log rank test. Analysis was conducted using 
Stata version 14 (StataCorp LLC, College Station, Texas, USA). 
 
 
3. RESULTS 
 
3.1. Eight-nine eligible women from 31 breast units were retrospectively identified. In all 
cases the initial DCIS diagnoses were made between 1998 and 2010 (no eligible cases 
diagnosed after 2010 were submitted despite specific requests for such cases). The DCIS 
was screen-detected in 39 women (44%), the others symptomatic. The median patient age 
at diagnosis was 75 years (range 44 - 94 years). The median duration of follow-up 
(diagnosis to death, invasive disease or last review) was 59 months (range 12 - 180 
months).  
 
Thirty-five women (39%) were recorded as being unfit for surgery (without details of the 
comorbidities), 37 (42%) declined surgery, four (4%) were both unfit and declined surgery, 
other (unspecified) reasons were stated for eight (9%) and the reasons were unknown for 
five (6%) patients. 
 
3.2. Mammographic features 
The predominant mammographic features were known for 75 of the 89 women. Fifty (67%) 
were microcalcification, granular microcalcification being the most common. Nine of the 25 
 women with other predominant features (mass or deformity) had microcalcification as a 
secondary feature. The median mammographic lesion size for women in whom both size 
and grade were known was 34 mm (range 8 - 88) for high grade DCIS (n=23), 32 mm (5 - 
126) for intermediate grade DCIS (n=23) and 15 mm (4 - 64) for low grade DCIS (n=11). 
 
3.3. Needle biopsy 
In 63 women, the initial DCIS diagnosis was made with 14-gauge (G) core needle biopsy 
(CNB). Only ten women were known to have been diagnosed with vacuum-assisted biopsy 
(VAB) (one each of 14G and 11G, five 10G and unknown gauge in three). In sixteen women, 
the biopsy technique was classed as either ‘other’ or unknown. Of the 72 women where the 
mode of guidance was known, 37 biopsies were performed under stereotaxis, 28 ultrasound 
and seven freehand. No DCIS diagnoses were made solely on fine needle aspiration 
cytology. 
 
3.4. Cytonuclear grade of DCIS and presence of microinvasion 
The grade of the DCIS at needle biopsy was known for 77 of the 89 women. Twenty-nine 
were high, 31 intermediate and 17 low grade. Microinvasion was only recorded as definitely 
present in one woman (grade unknown) and possibly present in four (one low grade, one 
intermediate grade, one high grade, one grade not known). Microinvasion was specifically 
stated to be absent on needle biopsy in 59 and not stated (presumed absent) in 25. 
 
3.5. Estrogen receptor (ER) status 
ER status was positive in 43 of the 48 women in whom ER was recorded (positivity was 
regarded as an Allred score ≥3/8 where the score was stated, otherwise as defined by the 
submitting centre). 
 
3.6. Non-surgical treatment 
 Forty-four women were treated with endocrine therapy (ET) - 26 with an aromatase inhibitor, 
17 with tamoxifen and one with each type sequentially. One woman treated with an 
aromatase inhibitor also received external beam radiotherapy. Thirty women treated with ET 
were recorded as having known ER positive DCIS. Thirty-five women received no ET; eight 
were known to have ER positive disease. Non-surgical treatment information was not 
available for 10 women. 
 
3.7. Development of invasive cancer 
Twenty-nine women (33%) had invasive breast cancer diagnosed histologically after a 
median interval of 45 months (range 12 - 144 months) following the initial DCIS diagnosis. A 
further five women who died had invasive breast cancer recorded as their primary cause of 
death on death certification but no histological confirmation of this was recorded on the 
cancer registry; these were not included amongst those who developed invasive cancer in 
this analysis as there is doubt about the accuracy of death certification. The 29 women who 
developed proven invasive cancer were significantly younger than the 60 who did not 
(median ages 67 years versus 78 years respectively; p=0.0002, Mann-Whitney U-Test). 
Younger women had a similar median length of follow-up to older women (age ≤70 years v. 
age>70 years: 60 months v. 58 months; p=0.45; Mann-Whitney U-test), although there was 
a non-significantly higher proportion of younger women with high grade disease (39% v. 
27%; p=0.26, Fisher exact test). 
 
One invasive cancer was recorded as having developed in the same breast but a different 
quadrant to the known high grade DCIS; this has been included as a case of DCIS 
progression for consistency with other published studies. As far as is known, the remaining 
28 invasive cancers developed at the site of the DCIS. 
 
Comparison of DCIS grade on the initial biopsy and the predominant mammographic feature 
for those with and without progression to invasive cancer is shown in Table 1. After median 
 intervals of 38, 60 and 51 months respectively, 14/29 (48%) women with high grade DCIS, 
10/31 (32%) with intermediate grade and 3/17 (18%) with low grade DCIS developed 
invasive cancer; grade was not known in 12. The cumulative incidence of invasive disease 
was significantly higher in women with high grade DCIS than in those with other grades 
(p=0.0016, log-rank test) – Figure 1. None of the five women with microinvasion on the initial 
biopsy developed invasive breast cancer. All six of the grade 3 invasive cancers occurred in 
women with a prior diagnosis of high grade DCIS (Table 2). 
 
Twenty-three of the 50 (46%) women with microcalcification as the predominant radiological 
feature developed invasion compared to only five of the 25 (20%) with another known 
predominant radiological feature (p=0.042, Fisher exact test).  
 
Nine of 44 women (20%) who received endocrine therapy developed invasive cancer 
compared to 15 of 35 (43%) who did not (p=0.048, Fisher exact test). 
 
Of the 25 known women who did not have microcalcification as the predominant feature, 
four of the 10 (40%) with secondary microcalcification developed invasive cancer compared 
to one of the 15 (7%) without microcalcification (p=0.12, Fisher exact test). 
 
3.8. Surgery 
Eighteen women ultimately underwent breast surgery, seventeen for invasive cancer: 
Thirteen had mastectomy and four wide local excision. One woman had a wide local 
excision for DCIS 12 months after initial diagnosis. 
 
3.9. Deaths 
Forty-eight women died. Eleven of these had biopsy-proven invasive cancer, of whom seven 
had a primary certified cause of death of breast cancer.   
 
 For women that developed invasive cancer the median interval from diagnosis to death was 
62 months for all-cause deaths and 62 months for deaths from breast cancer. For those that 
did not develop invasive cancer the median interval was 57 months (p=0.28, Mann-Whitney 
U-Test). 
 
Among the 29 women with invasive cancer, there was no significant difference between the 
age at diagnosis of DCIS for those who died compared with the women still alive at census 
(median ages 68 years v. 66 years respectively; p=0.62, Mann-Whitney U-Test). However, 
of the women who did not develop invasive cancer, those who died were significantly older 
at diagnosis than those who remained alive (median ages 83 years v. 69 years; p=0.0001, 
Mann-Whitney U-Test). 
 
 
4. DISCUSSION 
 
This retrospective longitudinal cohort study of women diagnosed with DCIS on core needle 
biopsy who did not undergo surgical excision for at least one year reviewed 89 eligible 
women. Progression to invasive breast cancer was more frequent in a short time frame for 
those with initial DCIS of high cytonuclear grade. The Kaplan-Meier analysis suggests that 
approximately 50% of women with high grade DCIS will develop invasive cancer within five 
years but fewer than 25% of those with lower grade DCIS will develop invasion in the same 
time frame. In particular, low grade DCIS appears to progress slowly to invasive cancer. For 
approximately one in seven of the women who died, the cause of death was attributed to 
breast cancer, with a median survival in these women of over five years from DCIS 
diagnosis. 
 
The tendency for high grade DCIS to be associated with grade 3 invasive cancer and the 
significantly higher cumulative incidence of invasion suggest that the biological behaviour is 
 reflected in the histopathological appearances of the DCIS. This effect of grade is similar to 
that seen for DCIS recurrence following surgical resection. [15] Our findings emphasise the 
importance of early detection and treatment of women with high grade DCIS in order to 
prevent the development of high grade invasive cancer. 
 
Even with the confounding factor of a slightly higher proportion of high grade disease in the 
younger (≤70 years) women, the rate of progression to invasion does appear to be higher in 
younger women. This is in keeping with the known higher local recurrence rate in younger 
women following surgical resection of DCIS. [1,16,17]  
 
The apparent association of DCIS microcalcification with the development of invasive 
disease has not been previously reported, although microcalcification has been shown to be 
associated with a higher risk of non-invasive recurrence. [18] In addition, there have been 
some suggestions that invasive cancers with microcalcification have a worse prognosis than 
non-calcified lesions, [19-21] although this is not a consistent finding [22] and may be due to 
confounding factors. [23] 
 
The effect of endocrine therapy in reducing progression of DCIS to invasive cancer noted 
here is consistent with the findings of trials of adjuvant endocrine therapy following surgery 
for DCIS. The UK/ANZ DCIS trial [24] and the NSABP B-24 study [25] demonstrated a 
significant reduction in the frequency of DCIS recurrence with tamoxifen, although the 
UK/ANZ study did not show a significant reduction in invasive recurrence. Anastrozole has 
subsequently been demonstrated to be at least as effective as tamoxifen in this setting. 
[26,27] 
 
The contribution of DCIS detection at screening to reduction of breast cancer mortality has 
long been debated. A review of prior mammograms of women with incident screen-detected 
cancers suggested that undiagnosed calcified DCIS progresses to invasive cancer within the 
 three-year period between screens in a significant number of women, [28] but only recently 
have data been published that demonstrate that high DCIS detection rates at screening are 
associated with a reduction in the incidence of interval cancers. [29] 
 
Sagara et al [4] reported outcomes of 57,222 women with DCIS from the SEER 
(Surveillance, Epidemiology and End Results) database, of whom 1169 (2%) had not 
undergone surgical resection. Although the development of invasive disease was not 
specifically examined, for women with high and intermediate grade DCIS there was a 
significant difference in 10-year breast cancer specific survival between those who 
underwent surgery and those who did not (98.4% v. 90.5%, p<0.001, for high grade; 98.6% 
v. 94.6%, p<0.001, for intermediate grade disease, respectively). Surgery was not, however, 
associated with a survival difference in women with low grade DCIS (98.6% v. 98.8%; 
P=0.95). A series following 14 women with ER positive DCIS who underwent endocrine 
therapy as an alternative to immediate surgery [6] reported that eight subsequently had 
surgery after a median follow-up of 28 months; five had with stage I invasive ductal cancers. 
Although there were only 17 women with low grade DCIS in the present study, eight died of 
non-breast cancer related causes and the findings suggest that low grade DCIS is a 
relatively indolent disease. Of the three women who did develop invasion after intervals of 
46, 51 and 137 months, one of the invasive cancers was of histological grade 1, one grade 2 
and the other was of unknown grade. These findings, together with the demonstrated lack of 
survival benefit from surgery, [4] also support ongoing studies of active surveillance as an 
alternative to surgery in low risk DCIS. [8-10] 
 
To our knowledge, this is the largest study reporting the progression of histologically 
confirmed unresected DCIS to invasive breast cancer. Diagnostic and treatment data were 
obtained from clinicians managing the women, supplemented by cancer registry data, and 
consequently data completeness is relatively high. Although variability in the application of 
diagnostic and grading criteria to DCIS by histopathologists is well recognised, [30] the 
 mandatory participation in a national quality assurance programme by all UK pathologists 
working in breast screening [31] provides some reassurance of uniformity of grading. 
 
This study has some limitations. Despite the large number of women with a DCIS diagnosis 
but no record of surgery on the cancer registries (2505 (5%) potentially eligible out of a total 
of 49,567 DCIS registrations in the period 1996-2009), only a relatively small number of 
patients (0.2%) had data submitted by the treating centres, with potential for selection bias. 
The proportion of women diagnosed with DCIS in the UK who do not undergo surgery is, 
therefore, unknown, but appears similar to the 2.0 - 2.3% reported in the USA. [4,13] 
Because of the nature of the study population (with regard to patient age and associated co-
morbidities), many of the women died during the course of the study, substantially limiting 
the duration of follow-up. Furthermore, there were relatively few younger women with 
screen-detected disease. The majority of women in the study underwent conventional core 
needle biopsy rather than vacuum-assisted biopsy for diagnosis. CNB is known to 
underestimate the coexistence of invasive disease in DCIS in approximately 20% of cases. 
[32-34] 
 Nonetheless, the study still allows a ‘real world’ approach to the outcome of DCIS 
diagnosed predominantly at CNB to be determined. Finally, due to the relatively small 
number of subjects, multivariate analysis was not possible, thus confounding factors cannot 
be excluded.  
 
 
5. CONCLUSIONS 
 
High cytonuclear grade of DCIS, mammographic microcalcification, young age and lack of 
endocrine therapy were significant risk factors for progression to invasive breast cancer after 
a median interval of 45 months in this group of women diagnosed with DCIS on needle 
biopsy but who did not undergo surgical resection for at least one year. These findings 
 suggest that complete surgical excision of high grade DCIS should continue to be 
undertaken as per current standard of care protocols, but that eligible women with low grade 
DCIS could be offered entry into active surveillance trials. 
 
 
  
 TITLE AND LEGEND TO FIGURE 
 
Figure 1. Cumulative incidence of invasive cancer by DCIS grade. 
Kaplan-Meier chart showing the cumulative incidence of invasive cancer from time of DCIS 
diagnosis by cytonuclear grade of DCIS. 
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